The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection—A Double Blind, Randomised, Placebo-Controlled Trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 426 adults randomised. 398 completed (194 on Levagen+, 204 on placebo).
- Dose used in the study
- 300 mg of Levagen+ twice a day
- Duration
- 12 weeks
- What was measured
- Number of upper respiratory tract infections; duration, symptom severity (WURSS-24), general health, sick days and adverse events
What the authors reported
This double-blind, randomised, placebo-controlled trial found:
- 39 infection episodes occurred in the Levagen+ group against 64 on placebo (p = 0.0056), with 32 participants affected on Levagen+ against 55 on placebo (p = 0.0116).
- Median severity scores were lower in the Levagen+ group for scratchy throat (3 vs. 7) and cough (2 vs. 7).
- Adverse events were similar in number between groups.
Limits of this study
The trial ran during the COVID-19 pandemic, which affected infection rates. Infections were self-reported and no biological samples were taken. The study was funded by Pharmako Biotechnologies.
Source
PubMed 37892528 · doi:10.3390/nu15204453
Entry checked against the abstract on PubMed, and the full text at the publisher (MDPI) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.